Drug-induced cutaneous lupus erythematosus after 5 years of treatment with carbamazepine

European Journal of Dermatology

Volumn 16, Issue 3, 2006, Pages 281-283

  Amerio, Paolo ^a   Innocente, Carmela ^a   Feliciani, Claudio ^b   Angelucci, Domenico ^c   Gambi, Domenico ^a   Tulli, Antonio ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^c Service of Pathology   (Italy)

Author keywords

Carbamazepine; Drug induced lupus erythematosus; Drug reaction

Indexed keywords

ANTINUCLEAR ANTIBODY; CARBAMAZEPINE; DOUBLE STRANDED DNA; GAMMA GLUTAMYLTRANSFERASE; IMMUNOGLOBULIN G; NEUTROPHIL CYTOPLASMIC ANTIBODY;

ACANTHOSIS; AGED; ANAMNESIS; ARTICLE; BLOOD CELL COUNT; BODY REGIONS; CASE REPORT; CLINICAL EXAMINATION; CLINICAL FEATURE; DESQUAMATION; EPILEPSY; ERYTHEMA; FEMALE; FOLLOW UP; HEAD INJURY; HUMAN; HYPERKERATOSIS; IMMUNOFLUORESCENCE TEST; KIDNEY FUNCTION TEST; LIVER FUNCTION TEST; MUSCLE WEAKNESS; MYALGIA; PROTEIN DETERMINATION; SKIN BIOPSY; SKIN DEFECT; SKIN INFLAMMATION; SKIN LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME;

AGED; CARBAMAZEPINE; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, CUTANEOUS;

EID: 33646713653     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Yung LR, Richardson BC. Drug-induced lupus. Rheum Dis Clin North Am 1994; 20: 61-6.
2. Antonov D, Kazandjieva J, Wetugov D, Gospodinov D, Tsankov N. Drug induced lupus erythematosus. Clin Dermatol 2004; 22: 157-60.
3. Egner W. The use of laboratory tests in the diagnosis of SLE. J Clin Pathol 2000; 53: 424-43.
4. Atzeni F, Marrazza MG, Sarzi-Puttini P, Carrabba M. Drug-induced lupus erythematosus. Reumatismo 2003; 55: 147-54.
5. Toepfer M, Sitter T, Lochmuller H, Pongratz D, Muller-Felber W. Drug-induced systemic lupus erythematosus after 8 years of treatment with carbamazepine. Eur J Clin Pharmacol 1998; 54: 93-4.
6. Feliciani C, Verzotti A, Coscione G, Toto P, Morelli F, Di Benedetto A, Saladini C, Chiarelli F, Tulli A. Skin reaction due to antiepileptic drugs: several case report with long term follow up. Int J Immunopath Pharmacol 2003; 16: 89-93.
7. Jain KK. Systemic lupus erythematosus (SLE)-like syndromes associated with carbamazepine therapy. Drug Saf 1991; 6: 350-60.
8. Sontheimer RD. Subacute cutaneous lupus erythematosus: 25-year evolution of a prototypic subset (subphenotype) of lupus erythematosus defined by characteristic cutaneous, pathological, immunological, and genetic findings. Autoimmun Rev 2005; 4: 253-63.
9. Werth VP, Zhang W, Dortzbach K, Sullivan K. Association of a promoter polymorphism to tumor necrosis factor alpha with subacute cutaneous lupus erythematosus and distinct photoregulation of transcription. J Invest Dermatol 2000; 115: 726-30.
10. Marzano AV, Borghi A, Mercogliano M, Facchetti M, Caputo R. Nitrendipine-induced subacute lupus erythematosus. Eur J Dermatol 2003; 13: 213-6.
11. Capponi A, De Simone C, Guerriero C, Rotoli M, Bartoloni C. Ro/SSA-positive cutaneous lupus erythematosus induced by carbamazepine. Arch Dermatol 2005; 141: 103-4.
12. Sontheimer RD, Thomas JR, Gilliam JN. Subacute cutaneous lupus erythematosus. A cutaneous marker for a distinct lupus erythematosus subset. Arch Dermatol 1979; 115: 1409-15.
13. Sontheimer RD. Subacute cutaneous lupus erythematosus: a decade's perspective. Med Clin North Am 1989; 73: 1073-90.
14. Shapiro M, Sosis AC, Junkin-Hopkins JM, Werth VP. Lupus erythematosus induced by medications, ultraviolet radiation, and other exogenous agents: a review with special focus on the development of subacute cutaneous lupus erythematosus in a genetically predisposed individual. Int J Dermatol 2004; 43: 87-94.